Faranoush Mohammad, Mehrvar Narjes, Sadeghi Yasaman, Tashvighi Maryam, Alebouyeh Mardawig, Mehrvar Azim
Pediatric Growth and Development Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.
MAHAK Hematology Oncology Research Center (MAHAK-HORC), MAHAK Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Int J Hematol Oncol Stem Cell Res. 2022 Apr 1;16(2):86-93. doi: 10.18502/ijhoscr.v16i2.9201.
The childhood cancer registry in Iran is a hospital-based system and there is not any unique and national registry system for pediatric malignancies in Iran. According to the limitations and requirements, this study was designed to clarify the aspect of childhood malignancies in Iran and promote establishing the Iranian national childhood cancer registry system. This cross-sectional longitudinal study was implied on 1500 patients younger than 20-years old diagnosed with any malignancy and admitted at MAHAK Pediatric Cancer Treatment and Research Center (MPCTRC) from 2007 to 2014. Data collection was based on a validated questionnaire with three categories including demographic data, clinical data and type of malignancy, and outcomes. Collected data were analyzed using methods for qualitative and quantitative variables (P < 0.05) by SPSS software version 22. The survival rate was calculated by the Kaplan-Meyer method. This study was implied on 1500 children with a mean age of 6.1 years old. The most common malignancy was acute leukemia (30.7%) followed by central nervous system tumors (27%). At the onset of starting treatment, the rate of conferring with relapse, metastasis, and secondary malignancies was 29%, 19.5%, and 1% respectively. In addition, 52 patients had bone marrow transplantation of whom, 14 cases died. Totally, 42% of patients died and the 3-years, 5-years, and 10-years overall survival rates were 67.7% ± 0.01, 60.3% ± 0.01, and 53.8% ± 0.01, respectively. Establishing a population-based pediatric cancer registry in Iran is necessary and will be useful for improving the survival rate of mentioned patients.
伊朗的儿童癌症登记系统是以医院为基础的，伊朗没有针对儿童恶性肿瘤的独特全国性登记系统。根据相关限制和要求，本研究旨在阐明伊朗儿童恶性肿瘤的情况，并推动建立伊朗全国儿童癌症登记系统。这项横断面纵向研究针对2007年至2014年期间在MAHAK儿童癌症治疗与研究中心（MPCTRC）确诊患有任何恶性肿瘤并入院的1500名20岁以下患者展开。数据收集基于一份经过验证的问卷，问卷分为三类，包括人口统计学数据、临床数据、恶性肿瘤类型及预后。收集到的数据通过SPSS 22版软件采用定性和定量变量分析方法进行分析（P<0.05）。生存率采用Kaplan-Meier法计算。本研究涉及1500名儿童，平均年龄为6.1岁。最常见的恶性肿瘤是急性白血病（30.7%），其次是中枢神经系统肿瘤（27%）。开始治疗时，复发、转移和继发性恶性肿瘤的发生率分别为29%、19.5%和1%。此外，52例患者接受了骨髓移植，其中14例死亡。共有42%的患者死亡，3年、5年和10年的总生存率分别为67.7%±0.01、60.3%±0.01和53.8%±0.01。在伊朗建立一个基于人群的儿童癌症登记系统是必要的，这将有助于提高上述患者的生存率。
